Prihlásiť sa Zaregistrujte sa zadarmo

Akcie v obehu spoločnosti Acelrx Pharmaceuticals Inc

Aká je hodnota metriky Akcie v obehu spoločnosti Acelrx Pharmaceuticals Inc?

Hodnota metriky Akcie v obehu spoločnosti Acelrx Pharmaceuticals Inc je 0.000 0.00%

Aká je definícia metriky Akcie v obehu?

Akcie v obehu (Shares float) je podiel akcií spoločnosti vlastnených verejnými investormi voči zablokovaným akciám (nie sú voľne v obehu).

Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded

The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.

Akcie v obehu spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Acelrx Pharmaceuticals Inc

Čomu sa venuje spoločnosť Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Firmy s metrikou akcie v obehu podobnou spoločnosti Acelrx Pharmaceuticals Inc